Cargando…

FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis

Aberrant expression of the Forkhead box transcription factor, FOXQ1, is a prevalent mechanism of epithelial-mesenchymal transition (EMT) and metastasis in multiple carcinoma types. However, it remains unknown how FOXQ1 regulates gene expression. Here, we report that FOXQ1 initiates EMT by recruiting...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Allison V., Wu, Ling, James Block, C., Zhang, Mu, Hackett, Justin, Craig, Douglas B., Chen, Wei, Zhao, Yongzhong, Zhang, Bin, Dang, Yongjun, Zhang, Xiaohong, Zhang, Shengping, Wang, Chuangui, Gibson, Heather, Pile, Lori A., Kidder, Benjamin, Matherly, Larry, Yang, Zhe, Dou, Yali, Wu, Guojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626503/
https://www.ncbi.nlm.nih.gov/pubmed/36319643
http://dx.doi.org/10.1038/s41467-022-34239-z
Descripción
Sumario:Aberrant expression of the Forkhead box transcription factor, FOXQ1, is a prevalent mechanism of epithelial-mesenchymal transition (EMT) and metastasis in multiple carcinoma types. However, it remains unknown how FOXQ1 regulates gene expression. Here, we report that FOXQ1 initiates EMT by recruiting the MLL/KMT2 histone methyltransferase complex as a transcriptional coactivator. We first establish that FOXQ1 promoter recognition precedes MLL complex assembly and histone-3 lysine-4 trimethylation within the promoter regions of critical genes in the EMT program. Mechanistically, we identify that the Forkhead box in FOXQ1 functions as a transactivation domain directly binding the MLL core complex subunit RbBP5 without interrupting FOXQ1 DNA binding activity. Moreover, genetic disruption of the FOXQ1-RbBP5 interaction or pharmacologic targeting of KMT2/MLL recruitment inhibits FOXQ1-dependent gene expression, EMT, and in vivo tumor progression. Our study suggests that targeting the FOXQ1-MLL epigenetic axis could be a promising strategy to combat triple-negative breast cancer metastatic progression.